GQG Partners
VRTX icon

GQG Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

GQG Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,387,263
Closed -$377M – 79
2020
Q3 		$377M Buy
1,387,263
+224,459
+19% +$61.9M 1.29% 27
2020
Q2 		$338M Buy
1,162,804
+445,157
+62% +$121M 1.48% 23
2020
Q1 		$171M Buy
717,647
+630,909
+727% +$145M 1.18% 26
2019
Q4 		$19M Buy
86,738
+78,933
+1,011% +$16M 0.13% 42
2019
Q3 		$1.32M Sell
7,805
-405,059
-98% -$71.7M 0.01% 40
2019
Q2 		$75.6M Sell
412,864
-101,995
-20% -$17.8M 0.81% 32
2019
Q1 		$94.4M Buy
+514,859
New +$95.1M 1.17% 28

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

GQG Partners's VRTX Position: Q4 2020 in Review

GQG Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2020, closing a stake of 1,387,263 shares — an estimated $377M sold.

GQG Partners first reported a position in VRTX in Q1 2019 and held it in 7 quarters. The position peaked at $377M in Q3 2020. 971 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

  • GQG Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • GQG Partners sold 1,387,263 Vertex Pharmaceuticals shares in Q4 2020, an estimated $377M.
  • GQG Partners first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 7 quarters.
  • GQG Partners's Vertex Pharmaceuticals position peaked at $377M in Q3 2020.
  • 971 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on GQG Partners's 13F filing for Q4 2020, filed 12 Feb 2021.